Cited by Cellular biology of the central nervous system

Quantitative comparison of the efficacy of clinical drug treatments for primary progressive multiple sclerosis DOI

Zichao Sui,

Haoxiang Zhu,

Jieren Luo

et al.

Journal of Clinical Neuroscience, Journal Year: 2023, Volume and Issue: 113, P. 45 - 53

Published: May 11, 2023

Language: Английский

Citations

The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis DOI

Xin Wu, Xin Tan, Jie Zhang

et al.

CNS Drugs, Journal Year: 2022, Volume and Issue: 36(11), P. 1155 - 1170

Published: Oct. 16, 2022

Language: Английский

Citations

Neuro‐immune interactions in health and disease: Insights from FENS‐Hertie 2022 Winter School DOI

Luisa Bandeira Binder, Priscila B. Rosa, Bárbara M. de Sousa

et al.

European Journal of Neuroscience, Journal Year: 2024, Volume and Issue: 59(8), P. 1977 - 1992

Published: Feb. 4, 2024

Abstract In a great partnership, the Federation of European Neuroscience Societies (FENS) and Hertie Foundation organized FENS‐Hertie 2022 Winter School on ‘Neuro‐immune interactions in health disease’. The school selected 27 PhD students 13 postdoctoral fellows from 20 countries involved 14 faculty members experts field. focused rising field research, between nervous both innate adaptive immune systems under pathological physiological conditions. A fine‐tuned neuro‐immune crosstalk is fundamental for healthy development, while disrupted communication might play role neurodegeneration, neuroinflammation aging. However, much yet to be understood about underlying mechanisms these brain scenarios. addition new findings this emerging field, novel methodologies animal models were presented foment research neuro‐immunology. provided an insightful knowledge exchange focusing latest discoveries biology fostering academic professional opportunities early‐career neuroscientists around world.

Language: Английский

Citations

Disease-modifying therapies as positive predictors of quality of life for Sudanese patients with multiple sclerosis: a cross-sectional study DOI

Eman Saleh Omar,

Hayat M. Suliman, Bashier Osman

et al.

The Egyptian Journal of Neurology Psychiatry and Neurosurgery, Journal Year: 2024, Volume and Issue: 60(1)

Published: June 20, 2024

Abstract Background Multiple sclerosis (MS) is an immune-mediated, neurodegenerative disease with devastating, disabling, and negative impacts on the patients’ quality of life (QoL). Although MS was not known in Sudan, it seems to be rising recent years. This a cross-sectional, hospital-based study aimed at assessing impact medications QoL neurology clinics Khartoum City. Sixty-four patients diagnosed were recruited. SF-36 questionnaire used assess QoL. Data collected from records addition hand-delivered questionnaire. analyzed using ANOVA test logistic regression; p ≤ 0.05 considered statistically significant. Results The majority females north Sudan (92.2%). mean age 28.2 ± 6.5. Relapsing–remitting most type (65.6%). Fatigue urinary incontinence observed symptoms. All had vitamin D deficiency (5–20 ng/ml). Disease-modifying therapies (DMTs) prescribed 37.5% patients. overall 53.9 14.7 fair physical mental health (51.8 19.2 57.0 10.9, respectively). Patients DMTs showed significantly good compared azathioprine ( 0.01), corticosteroids 0.01.), no 001). Azathioprine (OR = 0.12; 0.05), 0.14; 0.05) treatment 0.01; 0.001) negatively affected when DMTs. Vitamin supplementation 0.01) associated Conclusions prominent young females’ descendants Sudanese northern tribes. improve devastating effect QoL,

Language: Английский

Citations

Cellular biology of the central nervous system DOI

Jannik Leyendecker, Tobias Prasse,

Anjali Karp

et al.

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 49 - 96

Published: Sept. 20, 2024

Language: Английский

Citations